Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.
Hoekstra PJ, Troost PW, Lahuis BE, Mulder H, Mulder EJ, Franke B, Buitelaar JK, Anderson GM, Scahill L, Minderaa RB. Hoekstra PJ, et al. Among authors: minderaa rb. J Child Adolesc Psychopharmacol. 2010 Dec;20(6):473-7. doi: 10.1089/cap.2009.0071. J Child Adolesc Psychopharmacol. 2010. PMID: 21186965 Free PMC article. Clinical Trial.
A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, Pamulapati S, Buitelaar JK, Hoekstra PJ. Harfterkamp M, et al. Among authors: minderaa rb. J Am Acad Child Adolesc Psychiatry. 2012 Jul;51(7):733-41. doi: 10.1016/j.jaac.2012.04.011. Epub 2012 May 25. J Am Acad Child Adolesc Psychiatry. 2012. PMID: 22721596 Clinical Trial.
Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M, Buitelaar JK, Minderaa RB, van de Loo-Neus G, van der Gaag RJ, Hoekstra PJ. Harfterkamp M, et al. Among authors: minderaa rb. J Child Adolesc Psychopharmacol. 2013 Apr;23(3):194-9. doi: 10.1089/cap.2012.0012. Epub 2013 Apr 11. J Child Adolesc Psychopharmacol. 2013. PMID: 23578015 Clinical Trial.
Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change.
Harfterkamp M, Buitelaar JK, Minderaa RB, van de Loo-Neus G, van der Gaag RJ, Hoekstra PJ. Harfterkamp M, et al. Among authors: minderaa rb. J Child Adolesc Psychopharmacol. 2014 Nov;24(9):481-5. doi: 10.1089/cap.2014.0026. Epub 2014 Nov 4. J Child Adolesc Psychopharmacol. 2014. PMID: 25369243 Clinical Trial.
No evidence for predictors of response to atomoxetine treatment of attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder.
Harfterkamp M, van der Meer D, van der Loo-Neus G, Buitelaar JK, Minderaa RB, Hoekstra PJ. Harfterkamp M, et al. Among authors: minderaa rb. J Child Adolesc Psychopharmacol. 2015 May;25(4):372-5. doi: 10.1089/cap.2014.0142. Epub 2015 Apr 28. J Child Adolesc Psychopharmacol. 2015. PMID: 25919900 No abstract available.
151 results